PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

						_
A RANSMITTAL		Application Number		10/516,83	7	
FORM	Filing Date		August 9, 2005			
SE JOOJ PALLONIA	First Named Inventor		Robert Pa	ul Anderson		
		Art Unit		1644		
of all correspondence after i	initial filing)	Examiner Name		Nora Maur	reen Rooney	
Total Number of Pages in This Submissi		Attorney Docket Nu	mber	BTG0008-	101 (142769US01)	
	ENC! C	SURES (check all that	ann/v)			=
Fee Transm	Drawing(s			fter Allowanc	ce Communication to TC	
☐ Fee Atts					unication to Board	
iched/Authorized	Licensing	-related Papers		of Appeals an	d Interferences	
Amendmen t / Reply	Petition				unication to TC Brief, Reply Brief)	
After Fir.	Petition to	Convert to a				
lal	Provision	al Application		roprietary Inf	ormation	
Affidavits //declaration(s)		Attorney, Revocation of Correspondence		Status Letter		
t.	Address					
Extension of Time Request	Terminal	Disclaimer		Other Enclose please identify i		
Express /	Request	for Refund		Forms PTO SB/08a and SB/08b (9 pp.); (105)		
Express / Abandonment Request	CD, Num	ber of CD(s)	References Cited; (81) Reference Copies Submitted; Return Card.			ľ
Supritemental Information Disclosificemental Information /ure Statement	☐ Lar	ndscape Table on CD				
c entified Copy of Priority	Remarks	EXPRESS MAIL LABEL NO.: EV 770972316 US				
Document(s)		DATE OF DEPOSI	T : FEBR	RUARY 28, 20	007	
Reply to Missing Parts/ Incomplete Application						
Reply to Missing Parts						
under 37 CFR1.52 or 1.53						
SIG	NATURE OF	APPLICANT, ATTOR	NEY, O	RAGENT		
Firm	Cozen O'Conn	or .				
Signature	ell o					
Printed Name	rd, Ph.D.					
Date	Date February 28, 20			38,534		
	CERTIFICA	TE OF TRANSMISSI	ON/MAI	LING		
I hereby certify that this corresponder Service with sufficient postage as fi Alexandria, VA 22313-1450 on the dat	nce is being fac rst class mail	csimile transmitted to the in an envelope address	USPTO	or deposited	with the United States F for Patents, P.O. Box	ostal 1450,
Signature						
Typed or printed name				Date		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

### IN THE UNITED S' AND TRADEMARK OFFICE

Th re application of: Robert Anderson

Serial No.: 10/516,837

Group Art Unit: 1644

Filing Date: August 9, 2005

Examiner: Nora Maureen Rooney

Title: Therapeutic Epitope and Uses Thereof

EXPRESS MAIL LABEL NO: EV 770972316 DATE OF DEPOSIT: February 28, 2007

### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

### This Information Disclosure Statement is being filed:

	within three months of the filing date of the patent application.
	within three months of the date of entry into the national stage as set forth in
	37 C.F.R. § 1.491 of the international application.
$\boxtimes$	before the mailing date of a first Office Action on the merits.
	after the mailing date of a first Office Action on the merits, but before the
	mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of
	Allowance under 37 C.F.R. & 1.311, and accordingly is accompanied by:

		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
		or
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
		No fee is owed by the applicant(s).
	Stater Final C.F.R	cordance with 37 C.F.R. § 1.129(a), this Information Disclosure ment is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37 § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.
	Notice Issue	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a e of Allowance under 37 C.F.R. § 1.311, but before the payment of the Fee, and accordingly is accompanied by the Statement under 37 C.F.R. 7(e), (see "Statement," and "Fees" below).
$\boxtimes$	attach	es of the references (except the U.S. Patent documents) listed on the ned PTO Forms SB/08A and SB/08B, formerly known as PTO Form are enclosed.
	EXC	EPT THAT:
		In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
		In accordance with 37 C.F.R. § 1.98(d), copies of all references listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Forms 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.
		If the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

	The undersigned attorney hereby states that each item information contained
	in the Information Disclosure Statement was cited in a communication from a
	foreign patent office in a counterpart foreign patent application not more than
	three months prior to the filing of the Information Disclosure Statement.
Fees	
$\boxtimes$	No Fee is owed by the applicant(s).
	The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R
	§ 1.17(p) is enclosed herewith.
Metho	od of Payment of Fees
	Attached is a check in the amount of \$ This form is
	submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is
	submitted in duplicate.
$\boxtimes$	Please charge any deficiency or credit any overpayment to Deposit Account
	50-1275.
	No fee or Statement is required under 37 C.F.R. § 1.97(b).
	Respectfully submitted,
	50-1275.

\_

Paul K. Legaard, Ph.D. Registration No. 38,534

Dated: February 28, 2007

COZEN O'CONNOR, P.C. 1900 Market Street, 5<sup>th</sup> Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 701-2013 - Facsimile Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

sestitute for form 1449A/PTO

Eman el

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known					
Application Number	10/516,837				
Filing Date	August 9, 2005				
First Named Inventor	Robert Paul Anderson				
Art Unit	1644				
Examiner Name	Nora Maureen Rooney				
Attorney Docket Number	BTG0008-101 (142769US01)				

	U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	US- 4,710,461	12/01/1987	Komano et al			
	AB	US- 4,886,753	12/12/1989	Marcker et al			
	AC	US- 4,943,674	07/24/1990	. Houck et al			
	AD	US- 5,086,169	02/04/1992	Mascarenhas			
	AE	US- 5,097,025	03/17/1992	Benfey et al			
	AF	US- 5,107,065	04/21/1992	Shewmaker et al			
	AG	US- 5,110,732	05/05/1992	Benfey et al			
	AH	US- 5,187,267	02/16/1993	Comai et al			
	ΑĪ	US- 5,202,257	04/13/1993	Heinemann et al			
	AJ	US- 5,250,515	10/05/1993	Fuchs et al			
	AK	-US- 5,356,799	10/18/1994	Fabijanski et al			
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	AL	US- 5,428,146	06/27/1995	Logemann et al			
	AM	US- 5,459,252	10/17/1995	Conkling et al			
	AN	US- 5,495,007	02/27/1996	Thompson et al			
	AO	US- 5,589,583	12/31/1996	Klee et al			
	AP-	US- 5,589,610	12/31/1996	De Beuckeleer et al			
	AQ	US- 5,618,988	04/08/1997	Hauptmann et al			
	AR	US- 5,629,183	05/13/1997	Saunders et al			
	AS	US- 5,633,363	05/27/1997	Colbert et al			
	AT	US- 5,646,333	07/08/1996	Dobres et al			

		FOREIGN	PATENT DO	CUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Date/Filing Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>6</sup>
	ΛŪ	WO98/56811	12/17/98	Consejo Superrior De Investigaciones Cientificas		
	AV	WO99/58681	11/18/99	Consejo Superior De Investigaciones Certi		
	AW	WO97/47745	12/18/97	Consejo Superior De Investigaciones Certificas		
	AX	WO97/20058	06/05/97	Bay Zoltan Alkalmazott Kutatasi Alapitva		
	AY	EP 905 236	03/31/99	Med. Res. Council		
	AZ	WO99/53075	10/21/99	Du Pont		
	BA	WO00/47614	08/17/00	Pioneer Hi Bred Int.		
			1			

|--|

\*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known					
Application Number	10/516,837				
Filing Date August 9, 2005					
First Named Inventor Robert Paul Anderson					
Art Unit	1644				
Examiner Name	Nora Maureen Rooney				
Attorney Docket Number	BTG0008-101 (142769US01)				

	U.S. PATENT DOCUMENTS						
Examiner Cite		Document Number	Publication/Issue Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
	AA	US- 4,710,461	12/01/1987	Komano et al			
	AB	US- 4,886,753	12/12/1989	Marcker et al			
	AC	US- 4,943,674	07/24/1990	, Houck et al			
	AD	US- 5,086,169	02/04/1992	Mascarenhas			
	AE	US- 5,097,025	03/17/1992	Benfey et al			
	AF	US- 5,107,065	04/21/1992	Shewmaker et al			
	AG	US- 5,110,732	05/05/1992	Benfey et al			
	AH	US- 5,187,267	02/16/1993	Comai et al			
	ΑÏ	US- 5,202,257	04/13/1993	Heinemann et al			
	AJ	US- 5,250,515	10/05/1993	Fuchs et al			
	AK	-US- 5,356,799	10/18/1994	Fabijanski et al			
	AL	US- 5,428,146	06/27/1995	Logemann et al			
	AM	US- 5,459,252	10/17/1995	Conkling et al			
	AN	US- 5,495,007	02/27/1996	Thompson et al			
	AO	US- 5,589,583	12/31/1996	Klee et al			
	AP-	US- 5,589,610	12/31/1996	De Beuckeleer et al			
	AQ	US- 5,618,988	04/08/1997	Hauptmann et al			
	AR	US- 5,629,183	05/13/1997	Saunders et al			
	AS	US- 5,633,363	05/27/1997	Colbert et al			
	AT	US- 5,646,333	07/08/1996	Dobres et al			

		FOREIGN	PATENT DO	CUMENTS		
<b></b>	0.11-	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Examiner Cite Initials* No.1		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Date/Filing Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	ΑŬ	WO98/56811	12/17/98	Consejo Superrior De Investigaciones Cientificas		
	AV	WO99/58681	11/18/99	Consejo Superior De Investigaciones Certi		
	AW	WO97/47745	12/18/97	Consejo Superior De Investigaciones Certificas		
- 74	AX	WO97/20058	06/05/97	Bay Zoltan Alkalmazott Kutatasi Alapitva		
	AY	EP 905 236	03/31/99	Med. Res. Council		
	AZ	WO99/53075	10/21/99	Du Pont		
	BA	WO00/47614	08/17/00	Pioneer Hi Bred Int.		
	<b> </b>					

Examiner	. ]	Date	
Signature		Considered	

\*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/516,837 Filing Date August 9, 2005 First Named Inventor Robert Paul Anderson Group Art Unit 1644 **Examiner Name** Nora Maureen Rooney

stitute for form 1449A/PTO

(use as many sheets as necessary) Sheet of | 9 Attorney Docket Number BTG0008-101 (142769US01)

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BF	Ach, et al., "RRB1 and RRB2 encode maize retinoblastoma-related proteins that interact with a plant D-type cyclin and geminivirus replication protein," Mol. Cell Biol. (1997) 17:5077-5086.	
	BG	Albani, et al., "DcE2F, a functional plant E2F-like transcriptional activator from Daucus carota," J. Biol. Chem. (2000) 275:19258-19267	
,	вн	Bandara, et al., "Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F," EMBO J. (1993) 12:4317-4324.	
	ВІ	Bogre, et al., "Wounding induces the rapid and transient activation of a specific MAP kinase activity," Plant Cell (1997) 9:75-83.	
	ВЈ	Breeden and Nasmyth, "Regulation of the yeast HO gene," Cold Spring Harbor Symp. Quant. Biol. (1985) 50:643-650.	
	BK	Breeden, "Start-specific transcription in yeast," Curr. Topics Microbiol. Immunol. (1996) 208:95-127.	
	BL	de Jager, et al., "Retinoblastoma proteins implants," Plant Mol. Biol. (1999) 41:295-299.	
	ВМ	de la Luna, et al., "Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal," J. Cell Sci. (1996) 109:2443-2452.	
	BN	Denecke, et al., "Plant and mammalian sorting signals for protein retention in the endoplasmic reticulum contain a conserved epitope," EMBO J. (1992) 11:2345-2355	
	ВО	Doonan and Folbert, "Conserved and novel regulators of the plant cell cycle," Curr. Opin. Cell Biol. (1997) 9:824-830.	
	BP	Dynlacht B.D. et al., "DNA-binding and trans-activation properties of Drosphila E2F and DP proteins," Proc Natl Acad Sci U S A 1994 Jul 5;91(14):6359-63.	

	i		1
Examiner		Date	
4	l,	Julio	
Signature		Considered	
T Signature	1.	Considered	J

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DICOLOGUES	Application Number	10/516,837	
INFORMATION DISCLOSURE	Filing Date	August 9, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Robert Paul Anderson	
	Group Art Unit	1644	
(use as many sheets as necessary)	Examiner Name	Nora Maureen Rooney	
Sheet 4 of 9	Attorney Docket Number	BTG0008-101 (142769US01)	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BQ	Dyson, "The regualtion of E2F by pRB-family proteins," Genes Dev. (1998) 12:2245-2262.	
	BR	Fields and Song, "A novel genetic system to detect protein-protein interactions," Nature (1989) 340:245-246.	
	BS	Fountain, et al., "Isolation and characterization of a plant retinoblastoma-related gene from photoautotrophic cell suspension culture of Chenopodium rubrum L.," Plant Physiol. (1999) 119:363.	
	ВТ	Fuerst, et al., "Modulation of cyclin transcript levels in cultured cells of Arapidopsis thaliana," Plant Physiol. (1996) 112:1023-1033.	
	BU	Gillaspy G.E. et al., GenEmbl Accesion No. U39059, 18 November 1996	
	BV	Gillespie D. "The magic and challenge of DNA probes as diagnostic reagents," <i>Vet Microbiol</i> (1990), (3	
	BW	Girling, et al., "A new component of transcription factor DRTF1/E2F," Nature (1993) 362:83-87.	
	BX	Grafi, et al., "A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication," Proc. Natl. Acad. Sci. USA (1996) 93:8962-8967.	
	BY	Gutierrez, "DNA replication and cell cycle in plants: learning from geminiviruses," EMBO J. (2000) 19:792-799.	
	BZ	Gutierrez, "The retinoblastoma patway in plant cell cycle and development," Curr. Opin. Plant Biol. (1998) 1:492-497.	
	CA	Hiebert S.W. et al., "E2F-1: DP-1 induces P53 and overrides survival factors to trigger apoptosis," Mol Cell Biol (1995), 15(12): 6864-74.	

_		· · · · · · · · · · · · · · · · · · ·	,	<del>y</del>
ſ	Examiner	•	Date	
l	Signature		Considered ·	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/516,837 INFORMATION DISCLOSURE Filing Date August 9, 2005 STATEMENT BY APPLICANT First Named Inventor Robert Paul Anderson Group Art Unit 1644 (use as many sheets as necessary) **Examiner Name** Nora Maureen Rooney of 9 Attorney Docket Number BTG0008-101 (142769US01) Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
	СВ	Helin, et al., "Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation," Genes Dev. (1993) 7:1850-1861.	
	СС	Helin, et al., "Inhibition of E2F-1 trans-activation by direct binding of the retinoblastoma protein," Mol. Cell Biol. (1993) 13:6501-6508.	
	CD	Helin, et al., A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F," Cell (1992) 70:337-350.	
	CE	Huntley and Murray, "The plant cell cycle," Curr. Opin. Plant Biol. (1999) 2:440-446.	
	CF	Huntley, et al., "The maize retinoblastoma protein homologue ZmRb1 is regulated during leaf development and display conserved interactions with G1/S regulators and plant cyclins (D-type) proteins," Plant Mol. Biol. (1998) 37:155-169.	
·	CG	Kosugi and Obashi, "P.CF1 and PCF2 specifically bind to cis elements in the rice proliferating cell nuclear antigen gene," Plant Cell (1997) 9:1607-1619.	
	СН	Kozak, "At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cell," J Mol Biol (1987), 196:947-950.	
	CI	Krek, et al., "Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members," Science (1993) 262:1557-1560	
	CJ	Lipman, et al., "Rapid and sensitive protein similarity searches," Science (1985) 227:1435-1441	
	СК	Lowndes, et al., "Control of DNA synthesis genes in fission yeast by the cell cycle gene cdc10," Nature (1992) 355:449-453.	
	CL	Lui, et al., "The Aradiopsis Cdc2a-interacting protein ICK2 is structurally related to ICK1 and is a potent inhibitor of cyclin-dependent kinase activity in vitro," Plant J. (2000) 21:379-386.	

Examiner	Date Considered	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FEB 7, 8 7001 B

PTC/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known				
Application Number	10/516,837			
Filing Date	August 9, 2005			
First Named Inventor	Robert Paul Anderson			
Group Art Unit	1644			
Examiner Name	Nora Maureen Rooney			
Attorney Docket Number	BTG0008-101 (142769US01)			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	СМ	Magyar Z. et al., "Characterization of two distinct DP-related genes from Arabidopsis thaliana," FEBS Lett. 2000 Dec 1; 486(1):79-87.	
	CN	Mariconti L. et al., "The E2F family of transcription factors from Arabidopsis thaliana. Novel and conserved components of the retinoblastoma/E2F pathway in plants," <i>J Biol Chem</i> (2002), 277(12):9911-9. EPub 2002 Jan 10.	
	со	Martinez-Balbos, et al., "Regulation of E2F1 activity by acetylation," EMBO J. (2000) 19:662-671.	
	СР	Marzio, et al., "E2F family members are differently regulated by reversible acetylation," J. Biol. Chem. (2000) 275:10887-10892.	
	CQ	Mironov, et al., "Cyclin-dependent kinases and cell division in plants: the nexus," Plant Cell (1999) 11:509-521.	
	CR	Nakagami, et al., "Tobacco retinoblastoma-related protein phosphorylated by a distinct cyclin-dependent kinase complex with Cdc2/cyclin D in vitro," Plant J. (1999) 18:243-252.	
	CS	Nevins, "E2F: A link between the Rb tumor suppression protein and viral oncoproteins," Science (1992) 258:424-429.	
	СТ	Ormonroyd, et al., "A new member of the DP family, DP-3, with distinct protein products suggests regulatory role for alternative splicaing in the cell cycle transcription factor DRTF1/E2F," Oncogene (1995) 11:1437-1446.	
	CU	Othani and Nevins, "Functional properties of a Drosophila homolog of the E2F-1 gene," Mol. Cell Biol. (1994) 14:1603-1612	
	CV	Ouelette, et al., (TITLE UNKOWN) Oncogene (1992) 7:1075-1081	
	CW	Ramirez-Parra, et al., "Characterization of wheat DP, a heterodimerization partner of the paint E2F transcription factor which stimulates E2F-DNA binding," FEBS Lett. (2000) 486:73-78.	

Examiner	Date	
Signature	Considered	·

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known		
		D10	OL COLLDE	Application Number	10/516,837	
			CLOSURE	Filing Date	August 9, 2005	
STATEMENT BY APPLICANT				First Named Inventor	Robert Paul Anderson	
				Group Art Unit	1644	
(	use as many she	ets as	necessary)	Examiner Name	Nora Maureen Rooney	
Sheet	7	of	9	Attorney Docket Number	BTG0008-101 (142769US01)	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number(s), publisher, city and/or country where published.			
	СХ	Ramirez-Parra, et al., "The cloning of plant E2F, a retinoblastoma-binding protein, reveals unique and conserved features with animal G1/S regulators," Nucl. Acids, Res. (1999) 27:3527-3533.		
· · · · · ·				
	CZ	Riou-Kamlichi, et al., "Cytokinin activation of Aradiopsis cell division through a D-type cyclin," Science (1999) 283:1541-1544.		
	DA	Sandler SJ et al., "Inhibition of gene expression in transformed plants by antisense RNA," <i>Plant Molecular Biology</i> (1988), 11(3): 301-310.		
	DB	Sanford, et al., "Optimizing the biolistic process for diffesent biological applications," Methods Enzymol. (1993) 217:483-509.		
	DC	Sardet, et al., "E2F-4 and E2F-5, to members of the E2F family, are expressed in the early phases of the cell cycle," Proc. Natl. Acad. Sci. USA (1995) 92:2403-2407.		
	DD	Sawado T et al., "dE2F2, a novel E2F-family transcription factor in Drosophila melanogaster," Biochem Biophys Res Coimmun 1998 Oct 20;251(2):409-415.		
	DE	Scott, et al, "Model system for plant cell biology: GFP imaging in living onion epidermal cells," Biotechniques (1999) 26:1125-1132		
-	DF	Sekine, et al., "Isolation and characterization of the E2F-like gene in plants," FEBS Lett. (1999) 460:117-122.		
	DG	Shoemaker, et al., EMBL Acc. No. Al939068, August 3, 1999		
	DH	Slansky and Farnum, "Introduction to the E2F family: protein structure and gene reguation," Curr. Topics Microbiol. Immunol. (1996) 208:1-30.		

	·		
Examiner		Date	1
Signature	•	Considered	J

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/516,837 INFORMATION DISCLOSURE Filing Date August 9, 2005 STATEMENT BY APPLICANT First Named Inventor Robert Paul Anderson Group Art Unit 1644 (use as many sheets as necessary) **Examiner Name** Nora Maureen Rooney Attorney Docket Number BTG0008-101 (142769US01) Sheet

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	DI	Smith and Waterman, "Comparison of biosequences", Adv. Mathematics (1981) 2:482-489.		
	DJ	Suarez-Lopez and Gutierrez, "DNA replication of wheat dwarfgeminivirus vectors: effects of origin structure and size," Virology (1997) 227:389-399.		
	DK	Tao, et al., "Subunit composition determines E2F DNA-binding site specificity," Mol. Cell Biol. (1997) 17:6994-7007		
	DL	Umada, et al., "A distinct cyclin-dependent kinase-activating kinase of Aradiopsis thaliana," Proc. Natl. Acad. Sci. USA (1998) 95:5021-5026		
	DM	Van der Krol A.R. et al., "Inhibition of flower pigmentation by antisense CHS genes: promoter and minimal sequences requirements for antisense effect," <i>Plant Mol Biol</i> (1990), 14(4): 457-466.		
	DN	Varagona, et al., "Nuclear localization signal(s)-required for nuclear targeting of the maize regulatory protein Opaque-2," Plant Cell (1992) 4:1213-1227		
	DO	von Armin et al., "Cloning vectors for expression of green fluorescent protein fusion proteins in transgenic plants," Gene (1998) 221:35-43.		
	DP	von Armin, et al., "Light inactivation of Arabiopsis photomorphoenic repressor COP1 involves a cell-specific regulation of its nucleocytoplasmic partitioning," Cell (1994) 79:1035-1045		
	DQ	Wang, et al., "ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both cdc2a and CycD3, and its expression is induced by abcsic acid," Plant J. (1998) 15:501-510.		
	DR	Waterhouse et al., "Virus resistance and gene silencing: killing the messenger," <i>Trends Plant Sci.</i> (1999), 4(11); 452-457.		
	DS	Whisstock J.C. et al., "Prediction of protein function from protein sequence and structure," Q Rev Biophys (2003) 36(3):307 Review.		

			, <del></del>
Examiner	i ·	Date	·
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

LEB 5 8 JULY IN

PTO/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/516,837

Filing Date August 9, 2005

First Named Inventor Robert Paul Anderson

Group Art Unit 1644

Examiner Name Nora Maureen Rooney

(use as many sheets as necessary)

Sheet 9 of 9

Attorney Docket Number BTG0008-101 (142769US01)

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	DT	Wu CL et al., "In vivo association of E2F-family transcription factor in Drosophila melanogaster," Mol Cell Biol (1995); 15(5): 2536-46.	
	DU	Xie, et al., "GRAB proteins, novel members of the NAC domain family, isolated by their interaction with a geminivirus protein," Plant Mol. Biol. (1999) 39:647-656.	
	DV	Xie, et al., "Identification and analysis of a retinoblastoma binding motif in the replication protein of a plant DNA virus: requirement for efficient viral DNA replication," EMBO J. (1995) 14:4073-4082.	
	DW	Xie, et al., "Plant cells contain a novel member of the retinoblastoma family of growth regulatory proteins," EMBO J. (1996) 15:4900-4908.	
	DX	Zheng, et al., "Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP," Genes Dev. (1999) 13:666-674.	
	DY	Fleckenstein "Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process," <i>J Biol Chem</i> (2002) 277(37):34109-34116.	
	DZ	Fraser et al., "Coeliac disease: In vivo toxicity of the putative immunodominant epitope," <i>Gut</i> (2003) 52(12):1698-1702.	
	EA	Lundin et al., "Oats induced villous atrophy in coeliac disease," Gut (2003) 52(11):1649-1652.	
	ЕВ	van de Wal, "Glutenin is involved in the gluten-driven mucosal T cell response," Eur J Immunol (1999) 29(10):3133-3139.	

	 	· · · · · · · · · · · · · · · · · · ·
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.